Pfizer\'s Talzenna approved in Europe for HER2 advanced breast cancer with gBRCA12 mutations

Pfizer's Talzenna approved in Europe for HER2- advanced breast cancer with gBRCA1/2 mutations

Pfizer’s oral poly (ADP-ribose) polymerase (PARP) inhibitor Talzenna (talazoparib) has secured approval in Europe from the European Commission, the drugmaker has confirmed, as a monotherapy for the treatment of human epidermal growth factor receptor 2-negative (HER2-) locally advanced (LA) or metastatic breast cancer (MBC) in adult patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations.

The manufacturer also noted that eligible patients “should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced o

read more

More From BioPortfolio on "Pfizer's Talzenna approved in Europe for HER2- advanced breast cancer with gBRCA1/2 mutations"